Entering text into the input field will update the search result below

Buy Idexx Laboratories - Cramer's Lightning Round (7/31/18)

Aug. 01, 2018 7:12 AM ETIDXX, EVH, UNH, WES, DCP, ZBH, ABT, TRTN4 Comments


  • Triton International has a good yield.
  • UnitedHealth is a better pick than Evolent Health.
  • Cramer likes the medical device group.

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, July 31.

Bullish Calls

IDEXX Laboratories (IDXX): Hold on to it, as it's one of the best-acting stocks. The companies for anything genetic, anything biological, even if it is dogs and cats, are doing well.

Western Gas Partners (WES): "I think that these stocks are now undervalued. The one I've been looking at is DCP Midstream (DCP). That yields 7%, and they just bumped the dividend. So I think you're in the right spot, and I'm willing to go with you."

Zimmer Biomet (ZBH): The medical device sector is good. Cramer likes Abbott (ABT) as well.

Triton International (TRTN): Cramer is not crazy about containers, but the stock has a good yield.

Bearish Call

Evolent Health (EVH): The company's platform is good, but UnitedHealth (UNH) is the best of breed in that group considering it has "Optum."


Jim Cramer's Action Alerts PLUS: Check out Cramer's multi-million dollar charitable trust portfolio and uncover the stocks he thinks could be HUGE winners. Start your FREE 14-day trial now!

Get Cramer's Picks by email - it's free and takes only a few seconds to sign up

This article was written by

Mohit is the former Managing Editor for the Breaking News (India team) at Seeking Alpha. Currently working with Benzinga, he was with Seeking Alpha from January 2010 until August 2020. Before joining Seeking Alpha in January 2010, he worked with a start-up equity research firm in the capacity of a Team Leader tracking US company events and results.Born in the U.A.E, he spent most of my growing up years in Dubai. Currently, he resides in Mumbai, India.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.